Uncategorized

Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost

by Business Wire • 2017/04/11 • 0 Comments

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today announced the completion of the active recruitment phase of the Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost for the treatment of glaucoma.

← Los Angeles County Department of Health Services Study Involving Safety Net Connect’s eConsult System Demonstrates Significant Reduction in Wait Times and Increase in Completed Screenings for Diabetic Retinopathy

Careful counselling from clinicians may help alleviate anxiety in wAMD patients →

Post navigation